Margetuximab Versus Trastuzumab in Patients With ...
Margetuximab plus chemotherapy showed improved PFS and OS over trastuzumab plus chemotherapy in ERBB2-positive advanced breast cancer, with an ICER of $1,486,442.35/QALY, exceeding WTP. However, for CD16A-158F allele carriers, ICER decreased to $592,669.73/QALY, indicating potential cost-effectiveness in this subgroup.
Reference News
Margetuximab Versus Trastuzumab in Patients With ...
Margetuximab plus chemotherapy showed improved PFS and OS over trastuzumab plus chemotherapy in ERBB2-positive advanced breast cancer, with an ICER of $1,486,442.35/QALY, exceeding WTP. However, for CD16A-158F allele carriers, ICER decreased to $592,669.73/QALY, indicating potential cost-effectiveness in this subgroup.